Table 2. Cross-matching the national DDI rules with the list of high-priority DDI rules.
Rule No.* | List of high-priority DDI rules | National DDI rules | |||
---|---|---|---|---|---|
Object drug/class | Precipitant drug/class | No. of final pairs | No. of matched rules | No. of unmatched national rules | |
3 | Amphetamine and derivatives | MAO inhibitors | 60 | 6 | 54 |
4 | Atazanavir | PPI | 5 | 4 | 1 |
5 | Febuxostat | Azathioprine/mercaptopurine | 2 | 0 | 2 |
8 | SSRIs | MAO inhibitors | 55 | 4 | 51 |
11 | Irinotecan | Strong CYP3A4 inhibitors | 24 | 1 | 23 |
16 | Narcotic analgesics | MAO inhibitors | 30 | 3 | 27 |
20 | TCAs† | MAO inhibitors | 40 | 5 | 35 |
21 | QT-prolonging agents‡ | QT-prolonging agents‡ | 2,162 | 17 | 2,145 |
22 | Ramelteon | CYP1A2 inhibitors | 4 | 0 | 4 |
23 | Strong CYP3A4 inhibitors | Protease inhibitors | 60 | 2 | 58 |
25 | HMG Co-A reductase inhibitors | CYP3A4 inhibitors | 38 | 12 | 26 |
27 | CYP3A4 inhibitors | Ergot alkaloids and derivatives | 60 | 22 | 38 |
28 | Tizanidine | CYP1A2 inhibitors | 7 | 1 | 6 |
30 | Tranylcypromine | Procarbazine | 1 | 0 | 1 |
31 | Triptans | MAO inhibitors | 15 | 1 | 14 |
No. of class-pairs: 15 (100.0%) | No. of matched class-pairs 12 (80.0%) | ||||
No. of drug-pairs: 2,563 (100.0%) | No. of matched drug-pairs 78 (3.0%) |
DDI = drug-drug interaction, PPI = proton-pump inhibitors, SSRI = selective serotonin reuptake inhibitors, MAO = monoamine oxidase, TCAs = tricyclic antidepressants.
*Rule number in (13); †List of TCAs: Mayo Clinic, http://www.mayoclinic.org/diseases-conditions/depression/in-depth/antidepressants/art-20046983?pg=2; ‡QT-prolonging agents: https://www.crediblemeds.org (accessed May 15, 2015).